Table 1.
Main clinical and epidemiologic characteristics of individuals of this study
| Characteristics | HIC (n = 21) | ART-suppressed (n = 10) | HIV-1 negative (n = 8) | |
|---|---|---|---|---|
| EC (n = 13) | VC (n = 8) | |||
| Sex, no. (%) | ||||
| Female | 10 (77) | 3 (38) | 4 (50) | 6 (60) |
| Male | 3 (23) | 5 (62) | 4 (50) | 4 (40) |
| Age (years)ab | 45 (39–60) | 44 (39–47) | 47 (38–53) | 47 (36–51) |
| Study point | ||||
| Time since HIV-1 diagnosis (years)b | 9 (5.5–15) | 12.5 (7–16) | NA | – |
| CD4+ T cell (cells/μl)b | 1027 (834–1255) | 664 (563–1228) | 889 (678–1097) | 1043 (784–1581) |
| Plasma HIV RNA (copies/ml)b | < 50 | 641 (327–915) | < 40 | – |
| CD4/CD8 ratiob | 1.33 (1.24–1.61) | 0.91 (0.67–1.23) | 1.06 (0.73–1.5) | 1.69 (1.62–2.00) |
HIC HIV controllers, ART antiretroviral therapy, EC elite controllers, VC viremic controllers, NA not available
aAge at study point; bInterquartile ranges are shown in parenthesis